U.S. Markets closed

Synthetic Biologics agrees to acquire Clinical-Stage C. disease program

Synthetic Biologics announced that the company has entered into an agreement with Prev AbR to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile infection, the cause of hospital acquired infections, that may occur secondary to treatment with antibiotics. The assets include a pre-Investigational New Drug package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents intended to support an IND and Biologic License Application with the FDA.